Relay Therapeutics (RLAY) EBIT (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly EBIT of -$78.6 million for Q1 2026, up 7.4% year-over-year from -$73.2 million in Q1 2025, and down 29.62% quarter-over-quarter from -$60.6 million in Q4 2025.
Relay Therapeutics (RLAY) EBIT (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported EBIT for 8 consecutive years, with -$78.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 7.4% year-over-year to -$78.6 million; the TTM figure through Mar 2026 stood at -$296.5 million (up 19.22% YoY), while the FY2025 annual figure was -$302.7 million, up 18.72% from the prior year.
- EBIT retreated to -$78.6 million in Q1 2026 per RLAY's latest filing, from -$60.6 million in the prior quarter.
- Across five years, EBIT topped out at -$60.6 million in Q4 2025 and bottomed at -$106.0 million in Q2 2023.
- Historically, EBIT has averaged -$83.9 million across 5 years, with a median of -$84.9 million in 2025.
- Annual changes were most pronounced in 2022 — EBIT jumped 59.8% — and 2023, when it plunged 61.31%.
- Relay Therapeutics' EBIT stood at -$72.9 million in 2022, then dropped by 26.55% to -$92.2 million in 2023, then grew by 7.83% to -$85.0 million in 2024, then grew by 28.65% to -$60.6 million in 2025, then declined by 29.62% to -$78.6 million in 2026.
- Business Quant data shows RLAY's EBIT at -$78.6 million in Q1 2026, -$60.6 million in Q4 2025, and -$80.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -90.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -90.82 Mn |
| Mar 31, 2026 | -78.59 Mn |
| Dec 31, 2025 | -60.63 Mn |
| Sep 30, 2025 | -80.39 Mn |
| Jun 30, 2025 | -76.85 Mn |
| Mar 31, 2025 | -84.87 Mn |
| Dec 31, 2024 | -84.98 Mn |
| Sep 30, 2024 | -96.37 Mn |
| Jun 30, 2024 | -100.76 Mn |
| Mar 31, 2024 | -90.36 Mn |
| Dec 31, 2023 | -92.20 Mn |
| Sep 30, 2023 | -73.58 Mn |
| Jun 30, 2023 | -106.05 Mn |
| Mar 31, 2023 | -101.18 Mn |
| Dec 31, 2022 | -72.85 Mn |
| Sep 30, 2022 | -85.89 Mn |
| Jun 30, 2022 | -77.81 Mn |
| Mar 31, 2022 | -62.72 Mn |
| Dec 31, 2021 | -67.72 Mn |
| Sep 30, 2021 | -60.99 Mn |